Bain Capital-linked fund boosts Kailera Therapeutics (KLRA) common stake
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. reported that investment entities affiliated with Bain Capital Life Sciences increased their indirect stake. BCLS Fund IV Investments, L.P. bought 1,562,500 shares of common stock in an open-market purchase at $16.00 per share.
On the same date, BCLS Fund IV Investments, L.P. also acquired additional common stock through automatic 1:1 conversions of Series A-1 and Series B Preferred Stock upon the closing of Kailera’s initial public offering. After these transactions, BCLS Fund IV Investments, L.P. indirectly held 22,583,268 shares of Kailera common stock.
Positive
- None.
Negative
- None.
Insights
Bain Capital-linked entities boosted their Kailera common equity via open-market buying and IPO-related conversions.
The filing shows BCLS Fund IV Investments, L.P., an entity linked to Bain Capital Life Sciences, made an open-market purchase of 1,562,500 Kailera common shares at $16.00. Open-market purchases are active decisions and often carry more informational weight than automatic conversions.
In addition, Series A-1 and Series B Preferred Stock automatically converted into common stock on a 1:1 basis when Kailera’s initial public offering closed, eliminating those preferred positions. Following these steps, BCLS Fund IV Investments, L.P. indirectly held 22,583,268 common shares, consolidating its exposure entirely into common equity as reflected in this filing.
Insider Trade Summary
Net Buyer: 1,562,500 shares ($25,000,000)
Net Buy
5 txns
Insider
Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences IV General Partner, LLC, Bain Capital Life Sciences Fund IV, L.P., BCLS Fund IV Investments GP, LLC, BCLS Fund IV Investments, L.P.
Role
null | null | null | null | null
Bought
1,562,500 shs ($25.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A-1 Preferred Stock | 16,875,000 | $0.00 | -- |
| Conversion | Series B Preferred Stock | 4,145,768 | $0.00 | -- |
| Conversion | Common Stock | 16,875,000 | $0.00 | -- |
| Conversion | Common Stock | 4,145,768 | $0.00 | -- |
| Purchase | Common Stock | 1,562,500 | $16.00 | $25.00M |
Holdings After Transaction:
Series A-1 Preferred Stock — 0 shares (Indirect, See footnotes);
Series B Preferred Stock — 0 shares (Indirect, See footnotes);
Common Stock — 16,875,000 shares (Indirect, See footnotes)
Footnotes (1)
- Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Key Figures
Open-market purchase: 1,562,500 shares at $16.00
Series A-1 Preferred conversion: 16,875,000 shares
Series B Preferred conversion: 4,145,768 shares
+2 more
5 metrics
Open-market purchase
1,562,500 shares at $16.00
Common Stock bought by BCLS Fund IV Investments, L.P.
Series A-1 Preferred conversion
16,875,000 shares
Converted 1:1 into common upon IPO closing
Series B Preferred conversion
4,145,768 shares
Converted 1:1 into common upon IPO closing
Common shares held after transactions
22,583,268 shares
Indirectly held by BCLS Fund IV Investments, L.P.
Converted preferred positions remaining
0 shares
Series A-1 and B Preferred after 1:1 conversions
Key Terms
open-market purchase, derivative conversion, Series A-1 Preferred Stock, Series B Preferred Stock, +2 more
6 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
derivative conversion financial
"transaction_action": "derivative conversion""
Series A-1 Preferred Stock financial
"security_title": "Series A-1 Preferred Stock""
Series A-1 preferred stock is a specific class of company shares created in an early financing round that typically gives its holders priority over common shareholders for dividends and money if the company is sold or liquidates. Think of it as a special ticket with upfront privileges — often convertible into ordinary shares and sometimes carrying voting or protective rights — so investors use it to reduce risk and preserve control compared with ordinary stock.
Series B Preferred Stock financial
"security_title": "Series B Preferred Stock""
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
initial public offering financial
"upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
beneficial ownership financial
"each disclaims beneficial ownership of such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider activity did Bain Capital entities report in Kailera Therapeutics (KLRA)?
Entities affiliated with Bain Capital Life Sciences increased their Kailera stake. BCLS Fund IV Investments, L.P. bought 1,562,500 common shares at $16.00 and received additional shares through automatic conversion of Series A-1 and Series B preferred stock when the company’s initial public offering closed.